Reaffirming the preemptive authority of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.) and the Public Health Service Act (42 U.S.C. 201 et seq.) (including regulations thereunder) with respect to State laws that inhibit access to or use of any reproductive health product.

United States117e CongrèsHRES-1434House of Representatives
Mis à jour : 22 déc. 2022

Résumé

Aucun résumé n’est disponible.

Textes du projet de loi

Versions disponibles
Consulter le texte officiel

2 versions disponibles

Tous les dossiers disponibles sont affichés.

Chronologie

  1. Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

    House of Representatives

  2. Referred to the Subcommittee on Health.

    House of Representatives

  3. Passed/agreed to in House: Pursuant to the provisions of H. Res. 1529, H. Res. 1434 is considered passed House.

  4. Pursuant to the provisions of H. Res. 1529, H. Res. 1434 is considered passed House.

    House of Representatives